Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus PMB 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus PMB 200.
DIETHYLSTILBESTROL vs PMB 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
PMB 200 is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a calcium channel blocker (CCB). The ARB component blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. The CCB component inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, resulting in peripheral vasodilation and decreased blood pressure.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
2.5 mg orally once daily, increased to 5 mg after 2 weeks if tolerated; maximum 10 mg once daily.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life 12 hours (range 10-14 h) in adults with normal renal function; prolonged to 24-36 h in moderate renal impairment (CrCl 30-50 mL/min), necessitating dose adjustment
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Renal (80% unchanged, 15% as glucuronide conjugate), biliary/fecal (5%)
Category C
Category C
Estrogen
Estrogen/Progestin Combination
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."